To determine whether DcR3 binds to TRAIL, we preincubated AsPC-1 human pancreatic cancer cells with or without recombinant DcR3, TRAIL, or anti-TRAIL McAb, and then stained them with biotinylated anti-DcR3 followed by streptavidin-FITC. This evidence concerns the gene TNFSF10 and familial pancreatic carcinoma.